Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer patients get extended access to promising immunotherapy

NCT ID NCT03768063

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing access and monitor long-term safety, not to test new effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atezolizumab (Tecentriq), sometimes with bevacizumab or alectinib
What this could lead to
If successful, this study could confirm that long-term atezolizumab treatment is safe and effective for controlling cancer in patients who already responded.
What could go wrong
This is an extension study, not a new treatment test. It only includes patients already benefiting, so results may not apply to all cancer patients. Side effects from long-term immune therapy remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2019

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible for continuing atezolizumab-based therapy at the time of roll-over from the parent study, as per the parent study protocol or * Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent * Time between the last dose of treatment received in parent study and first dose in extension study is no longer than the interruption period allowed in the parent study. First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study * Continue to benefit from atezolizumab-based study treatment or from the comparator at the time of roll-over from the parent study as assessed by the investigator * Negative serum pregnancy test within 7 days prior to start of study treatment in women of childbearing potential * For women of childbearing potential: agreement to remain abstinent or use contraceptive methods, and agreement to refrain from donating eggs * For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm Exclusion Criteria: * Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study * Study treatment or comparator agent is commercially marketed in the patient's country for the patient-specific disease and is accessible to the patient * Treatment with any anti-cancer treatment during the time between last treatment in the parent study and the first dose of study treatment in this extension study * Permanent discontinuation of atezolizumab for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable). Exception: Participants who permanently discontinued atezolizumab from parent studies that permit participants to continue treatment with the combination agent(s) alone after permanently discontinuing atezolizumab are eligible to enroll in this study. * Ongoing serious adverse event(s) that has not resolved to baseline level or Grade ≤1 from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in this extension study * Any condition that, in the opinion of the investigator, would interfere with the interpretation of patient safety or place the patient at high risk for treatment-related complications * Concurrent participation in any therapeutic clinical trial (other than the parent study) * Pregnant or lactating, or intending to become pregnant during this extension study and for the period after the last dose of study treatment specified in the designated referenced safety information (RSI)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Anticancer Hospital Ag. Savas

    Athens, 11522, Greece

  • Arkhangelsk Regional Clinical Oncology Dispensary

    Arkhangelsk, Arhangelsk, 163045, Russia

  • Asan Medical Center, Uni Ulsan Collegemedicine

    Seoul, 138-736, South Korea

  • Asklepios-Fachklinik Muenchen-Gauting

    Gauting, 82131, Germany

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • CHU Angers

    Angers, Pays de la Loire Region, 49933, France

  • Carolina BioOncology Institute, PLCC

    Huntersville, North Carolina, 28078, United States

  • Centre Antoine Lacassagne

    Nice, Provence-Alpes-Côte d'Azur Region, 06189, France

  • Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez

    Lille, 59037, France

  • Centrul de Oncologie Oncohelp

    Timișoara, 300239, Romania

  • Centrul de Oncologie Sfantul Nectarie

    Craiova, 200347, Romania

  • Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Clinica Universidad de Navarra-Madrid

    Madrid, 28027, Spain

  • Communal Non profit Enterprise Regional Center of Oncology

    Kharkiv, Kharkiv Governorate, 61070, Ukraine

  • Dolnoslaskie Centrum Onkologii

    Wroc?aw, 53-412, Poland

  • Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii

    Otwock, 05-400, Poland

  • Faculty of Med. Siriraj Hosp.

    Bangkok, 10700, Thailand

  • Grupo Angeles

    Guatemala City, 01015, Guatemala

  • Hokkaido University Hospital

    Hokkaido, 060-8648, Japan

  • Hospital Universitario Madrid Sanchinarro

    Madrid, 28050, Spain

  • Hospital Universitario Quiron Dexeus

    Barcelona, 08028, Spain

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Institut Gustave Roussy

    Villejuif, Île-de-France Region, 94805, France

  • Institut Jules Bordet

    Brussels, 1000, Belgium

  • Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca

    Cluj-Napoca, 400015, Romania

  • Institutul Regional de Oncologie Iasi

    Iași, 700483, Romania

  • Istituto Nazionale dei Tumori

    Milan, Lombardy, 20133, Italy

  • Kanazawa University Hospital

    Ishikawa, 920-8641, Japan

  • Kliniken Essen-Mitte

    Essen, 45136, Germany

  • Krankenhaus Barmherzige Bruder Regensburg

    Regensburg, Bavaria, 93049, Germany

  • Kyushu University Hospital

    Fukuoka, 812-8582, Japan

  • Laiko General Hospital Athen

    Athens, 115 27, Greece

  • Lungenfachklinik Immenhausen

    Immenhausen, 34376, Germany

  • ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council

    Kryvyi Rih, 50048, Ukraine

  • Masaryk?v onkologický ústav

    Brno, 656 53, Czechia

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy

    Otwock, 05-400, Poland

  • Metropolitan Hospital

    Piraeus, Attica, 18547, Greece

  • Multiprofile Hospital for Active Treatment Central Onco Hospital OOD

    Plovdiv, 4004, Bulgaria

  • NHO Kinki-Chuo Chest Medical Center

    Sakaishi, 591-8555, Japan

  • Nagoya University Hospital

    Aichi, 466-8560, Japan

  • Narodowy Instytut Onkologii im. Marii Sk?odowskiej-Curie - Pa?stwowy Instytut Badawczy

    Warsaw, 02-781, Poland

  • National Cancer Institute MOH of Ukraine

    Kiev, 36022, Ukraine

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, 810-8563, Japan

  • National Hospital Organization Shikoku Cancer Center

    Ehime, 791-0280, Japan

  • Niigata University Medical & Dental Hospital

    Niigata, 951-8520, Japan

  • Osaka Habikino Medical Center

    Osaka, 583-8588, Japan

  • P.A. Herzen Oncological Inst.

    Moscow, Moscow Oblast, 125248, Russia

  • Phylasis Clinicas Research S de RL de CV

    Toluca, 50090, Mexico

  • Pontificia Universidad Catolica de Chile

    Santiago, 8330032, Chile

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary

    Sumy, 40022, Ukraine

  • Rigshospitalet

    København Ø, 2100, Denmark

  • Russian Oncology Research Center n.a. N.N. Blokhin

    Moscow, Moscow Oblast, 115478, Russia

  • SRH Wald-Klinikum Gera

    Gera, 07548, Germany

  • Samsung Medical Center

    Seoul, 6351, South Korea

  • Sendai Kousei Hospital

    Miyagi, 981-0914, Japan

  • Seoul National University College of Medicine, Liver Research Institute

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital

    Seoul, 03722, South Korea

  • St Vincent'S Hospital

    Darlinghurst, New South Wales, 2010, Australia

  • St. Luke's Cancer Care Associates

    Bethlehem, Pennsylvania, 18015, United States

  • Szegedi Tudományegyetem

    Szeged, Hungary

  • Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny

    Brzozów, 36-200, Poland

  • UZ Brussel

    Brussels, 1090, Belgium

  • UZ Leuven

    Leuven, Flemish Brabant, 3000, Belgium

  • Universitaets-Hautklinik Tuebingen

    Tübingen, 72076, Germany

  • Universitaetsklinikum Muenster

    Münster, 48149, Germany

  • Universitaettsklinikum Tübingen

    Tübingen, 72076, Germany

  • University of Colorado Cancer Center

    Aurora, Colorado, 80045, United States

  • University of Texas Health Sciences Center in San Antonio

    San Antonio, Texas, 78229, United States

  • University of Tsukuba Hospital

    Ibaraki, 305-8576, Japan

  • Universitätsklinik Tübingen

    Tübingen, 72076, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, 79106, Germany

  • Universitätsklinikum Schleswig-Holstein;Campus Lübeck

    Lübeck, Schleswig-Holstein, 23538, Germany

  • Universitätsklinikum Ulm

    Ulm, Baden-Wurttemberg, 89081, Germany

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Pozna?, Greater Poland Voivodeship, 60-569, Poland

  • Volyn Regional Oncology Dispensary

    Lutsk, 43018, Ukraine

  • Yale University School Of Medicine

    Trumbull, Connecticut, 06611, United States

  • hopital de la Timone

    Marseille, 13005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.